Pheno therapeutics
- Company typePrivate
- Founded2017
- HeadquartersEdinburgh, United Kingdom
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Pheno therapeutics firmographics
Firmographics- Name
- Pheno therapeutics
- Legal name
- Pheno Therapeutics Limited
- Website
- https://phenotherapeutics.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Pheno therapeutics industry classification
Industry- Product category
- Multiple Sclerosis Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industries
- Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD), Translational Medicine & Biomarkers (HLAIALAF)
Keywords
Where Pheno therapeutics is headquartered
LocationHeadquarters
- HQ city
- Edinburgh
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Pheno therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Development and Commercialization: As a clinical-stage biotechnology company, Pheno Therapeutics is developing small molecule therapeutics for the treatment of neurological diseases. The company plans to commercialize its pipeline through eventual pharmaceutical partnerships or direct commercialization. Revenue will be derived from licensing deals, milestone payments, androyalties on net sales from developed therapeutics.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Pheno therapeutics product offering
Product offeringCore offering
Pheno Therapeutics is a clinical-stage biotech developing small molecule GPR17 antagonists designed to promote remyelination in neurological diseases, with lead candidate PTD802 advancing through first-in-human trials for multiple sclerosis. The company leverages a proprietary human phenotypic screening platform to discover targets that modulate oligodendrocyte biology, developing therapeutics under an exclusive worldwide license from UCB. Its pipeline addresses demyelinating disorders including MS, Alzheimer's disease, ALS, Parkinson's disease, and rare leukodystrophies.
Product overview
Pheno Therapeutics is a clinical stage biotech company developing a portfolio of small molecule GPR17 antagonists for neurodegenerative and demyelinating disorders. The lead product is PTD802, a selective GPR17 antagonist designed to promote remyelination for multiple sclerosis treatment. The company operates a GPR17 antagonist discovery platform that leverages proprietary human phenotypic screening to identify novel molecules that boost oligodendrocyte function and natural remyelination capacity.
Differentiator
Problem solved
Functional benefit
Products and services
- PTD802 PTD802 is a selective GPR17 antagonist and novel small molecule therapeutic candidate designed to promote remyelination in neurological diseases, with initial focus on multiple sclerosis. It is the first GPR17 programme to receive FDA IND clearance globally and is being advanced under an exclusive worldwide license from UCB into first-in-human clinical trials.
- GPR17 Antagonist Discovery Platform A proprietary human phenotypic screening and drug discovery platform that harnesses GPR17 biology to identify small molecules that boost oligodendrocyte function and unlock the brain's endogenous remyelination capacity, serving as the engine for Pheno Therapeutics' GPR17 antagonist pipeline.
Quantifiable outcome
- GPR17 receptor blockade enables promotion of remyelination in neurological diseases
- +1 more outcomes
Companies that use Pheno therapeutics
Customer profileSegments2 records
Ideal customer profiles2 records
Pheno therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Pheno therapeutics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- UCBcorePheno Therapeutics entered into an exclusive worldwide license agreement with UCB in January 2023. The agreement grants Pheno Therapeutics access and rights to develop, manufacture and commercialize a preclinical-stage program of novel small molecules designed to promote remyelination. The license covers the GPR17 program including PTD802. UCB receives milestones and tiered royalties on net sales.
- University of EdinburghcoreOriginal research by Professors Siddharthan Chandran and Neil Carragher of the University of Edinburgh formed the basis for Pheno Therapeutics. The company combines world leading expertise in myelin biology, MS trials, patient selection and clinical cohorts from academic founders.
- Edinburgh InnovationscoreThe University's commercialisation service that helped bring together the scientific and clinical expertise in partnership with Advent Life Sciences to launch the company. Supported the formation of Pheno Therapeutics by facilitating partnership between academic founders and venture capital.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Pheno therapeutics competitors and assessment
Company assessmentDirect peers
- Clene Nanomedicine: Clinical-stage company developing CNM-Au8, a gold nanocatalyst designed to promote remyelination and neuroprotection in MS and other neurological diseases — directly comparable mechanism and indication focus.
- Pipeline Therapeutics: Clinical-stage biotech developing remyelination and neuroprotective therapies for MS and other CNS disorders; competes in the same disease-modifying remyelination space as PTD802.
- MediciNova: Clinical-stage company developing ibudilast (MN-166) for progressive MS and other neurological conditions; a peer in MS drug development with CNS anti-inflammatory/neuroprotective focus.
Broad incumbents
- Biogen: Global MS market leader with Tysabri, Avonex, and Plegridy; defines the standard of care Pheno's remyelination approach would need to improve upon, and is a natural acquirer/partner for late-stage CNS assets.
- Novartis: Holds major MS franchise assets (Gilenya, Kesimpta) and is the largest pharma in neuroscience; a relevant comparator as a potential commercial partner or acquirer for remyelination therapies.
- Roche: Owns Ocrevus, the leading high-efficacy MS therapy, and has CNS R&D investments; comparable as the dominant benchmark in MS therapeutics.
Emerging players
- Alector: Clinical-stage biotech developing immuno-neurology therapies for neurodegenerative diseases (Alzheimer's, FTD); relevant emerging peer in the broader CNS neurodegeneration space Pheno's pipeline targets.
- Anavex Life Sciences: Clinical-stage biotech developing small molecules (e.g., blarcamesine) targeting CNS indications including MS and neurodegenerative diseases; an emerging player in the same therapeutic space.
Others
- Verge Genomics: AI-driven CNS drug discovery company; linked via Chair Jane Rhodes (former President & CBO) and represents the broader neurodegenerative drug discovery ecosystem that Pheno Therapeutics operates within.
- Karuna Therapeutics: CNS-focused biotech (now part of BMS) that developed xanomeline for CNS indications; serves as a relevant precedent for clinical-stage CNS biotechs achieving major pharma exits and validates the commercial attractiveness of CNS assets.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Pheno therapeutics social profiles
Digital presencePheno therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pheno therapeutics leadership team
Management profileNumber of profiles
Profiles7 records
Pheno therapeutics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pheno therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pheno therapeutics
What does Pheno therapeutics do?
Pheno Therapeutics is a clinical-stage biotech developing small molecule GPR17 antagonists designed to promote remyelination in neurological diseases, with lead candidate PTD802 advancing through first-in-human trials for multiple sclerosis. The company leverages a proprietary human phenotypic screening platform to discover targets that modulate oligodendrocyte biology, developing therapeutics under an exclusive worldwide license from UCB. Its pipeline addresses demyelinating disorders including MS, Alzheimer's disease, ALS, Parkinson's disease, and rare leukodystrophies.
Is Pheno therapeutics a public or private company?
Pheno therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Pheno therapeutics founded?
Pheno therapeutics was founded in 2017. It employs 101 to 250 people.
Where is Pheno therapeutics based?
Pheno therapeutics is headquartered in Edinburgh, United Kingdom, in the Europe region.
How does Pheno therapeutics make money?
One revenue line is on record: pharmaceutical Development and Commercialization.
Who are Pheno therapeutics's main competitors?
Direct peers on record are Clene Nanomedicine, Pipeline Therapeutics and MediciNova. Broad incumbents are Biogen, Novartis and Roche. Emerging players are Alector and Anavex Life Sciences. Others are Verge Genomics and Karuna Therapeutics.
Does Pheno therapeutics have an API?
No public API is recorded for Pheno therapeutics.
What industry is Pheno therapeutics in?
Pheno therapeutics's product category is Multiple Sclerosis Therapeutics. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2834.